IOVA
Iovance Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.79
+1.03%Aug 21, 2026, 21:15 UTC
Iovance Biotherapeutics granted inducement stock options covering 240,135 shares of common stock to twenty new non-executive employees on August 20, 2026.
Source:Aug 6, 2026, 11:01 UTC
The FDA granted Fast Track Designation to Iovance Biotherapeutics for Lifileucel in soft tissue sarcomas.
Source:Aug 6, 2026, 11:01 UTC
Iovance Biotherapeutics reported record second quarter 2026 revenue of approximately $99 million, up 66% year-over-year, with U.S. Amtagvi revenue reaching about $91 million and gross margin increasing to 56%.
Jun 3, 2026, 20:05 UTC
Iovance Biotherapeutics received regulatory approval from Australian authorities for its T cell therapy Amtagvi (lifileucel) to treat advanced melanoma.
Source:Jun 1, 2026, 16:32 UTC
Iovance Biotherapeutics obtained FDA clearance of an Investigational New Drug application for IOV-5001, extending its cell therapy platform into solid tumors.
Source: